Bigfinite, Inc., an industry-leading AI and machine learning company that caters to the pharma and biotech sectors, recently announced that it has changed its corporate name to Aizon as of October 5, 2020.
According to a press release from the company, the change “highlights Aizon’s expertise in providing cutting-edge artificial intelligence (AI) and machine learning (ML) capabilities and reflects the expansion of the company mission to serve additional regulated industries including animal health, cosmetics, medical devices, specialty chemicals, nutraceuticals and food and beverage.”
Aizon hopes that the rebrand will help drive its superior AI and ML-driven analytical platforms to help serve a wide range of industries within the life science and food sectors.
Related: AI Algorithm Qualification
“This is a symbol of change, not a change of symbol. Markets are increasingly in need of advanced artificial intelligence, flexible IoT data acquisition, compliant data lakes, deep learning and other industrial-grade technologies. Aizon is well positioned to help those manufacturing sectors meet stringent regulatory requirements and extract deeper understanding of complex processes, which ultimately leads to new sources of value,” said John Vitalie, chief executive officer of Aizon, in the press statement from the company.
As a provider of AI software and machine learning-based analytical platforms, Aizon is committed to revolutionizing manufacturing operations through increased efficiencies. Using this approach, companies within regulated industries can optimize production with the use of advanced analytics, artificial intelligence and other smart factory technologies.
Aizon’s AI platform integrates structured and unstructured data to deliver actionable insights across various types of manufacturing sites. Aizon says it offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.
Aizon’s AI Consulting
Alongside the name change and market expansion, Aizon is gearing up to launch AI Consulting Services, which the company says is “designed to work both collaboratively with system integrators and independently, with a focus on achieving results and value from AI/ML.”
As part of the program, Aizon will share its expertise on the application of AI/ML-driven approaches in manufacturing operations to enhance efficiencies.
The company’s consulting services will “include executive strategy workshops and blueprint services designed to help companies align the practical implementation of AI/ML with their current scope and future vision of manufacturing operations and quality systems.”
“We are partnering and meeting our customers where they are, to help them and their stakeholders undergo digital transformation on their own timeline and based on their definition of value,” said Vitalie. “The ultimate goal is to leverage our scalable platform to deliver smart and compliant manufacturing.”
Bigfinite has been a trusted name in AI and machine learning analytical platform deliveries for the pharma and biotech sectors, and now as Aizon, it hopes to lend its expertise to new manufacturing areas and at larger scales.
Pharma Rebrands: Fresh Starts and New Meaning
Organizational restructuring and rebranding are not new in the pharma and biotech world. Apart from mergers and acquisitions between companies, restructuring within organizations (with new demarcations, additions or eliminations) can drive companies to redirect or expand their focuses and initiatives. A fresh or renewed start can be effectively facilitated with a corporate name change to reflect changes in a company’s values, missions and interests.
As another recent example, genomics data company Wuxi NextCODE underwent restructuring and has emerged under the new name Genuity Science. The company decided to streamline its operations and released an overseas faction of the organization to help achieve its current and future goals.
Some renames can lend organizations a new identity, particularly if a company is aiming to reinvent itself.
And in other cases, a new name can add new meaning. For example, Quebec-based pharma company Valeant Pharmaceutical International changed its name to Bausch Health Companies Inc. (NYSE/TSX: BHC) in 2018. The company’s chairman and CEO, Joseph C. Papa, said that the new corporate name was “very meaningful, because the Bausch name has long been a highly respected name in the healthcare space, synonymous for 165 years with innovation and an unwavering dedication to improving people’s lives. It is a legacy that defines us today and sets the stage for our future as we continue to transform the company.”
Company rebrands can also heighten interest from both investor and consumer perspectives, with prices of shares generally spiking after rebranding announcements.
With Bigfinite’s rebranding to Aizon, the company aims to expand its expertise to serve more diverse and large scale clientele in pharma and biotech that can benefit from AI and ML approaches in their manufacturing operations.